Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma

Clinical Lymphoma

Volumn 5, Issue SUPPL. 1, 2004, Pages

  Borghaei, Hossein ^a   Wallace, Stephen G ^a   Schilder, Russell J ^a,b  

^a FOX CHASE CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

Antibody; CHOP; Myelosuppression; Radioimmunotherapy; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TOXICITY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELLULITIS; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DOSIMETRY; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; FEBRILE NEUTROPENIA; HUMAN; ISOTOPE LABELING; LEUKEMIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; OSTEOMYELITIS; OUTCOMES RESEARCH; PNEUMONIA; PREDICTION; RADIOIMMUNOTHERAPY; SEPSIS; THROMBOCYTOPENIA; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 7744223575     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2004.s.004     Document Type: Article

References (29)

1. Armitage JO, Mauch PM, Harris NL, et al. Non-Hodgkin's lymphomas. In: DeVita VT, Hellman S, Rosenberg SA, eds. Principals and Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
2. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-1545.
3. McLaughlin P, Grillo-Lopez A, Link B, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
4. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17:268-276.
5. Czuczman MS, Grillo-Lopez AJ, LoBuglio AI, et al. Patients with low-grade NHL treated with rituximab + CHOP experience prolonged clinical and molecular remission. Blood 2003; 102(suppl):411a (Abstract #1493).
6. Keating M, O'Brien S. High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol 2000; 27(6 suppl 12):86-90.
7. Wagner HN Jr, Wiseman GA, Marcus CS, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002; 43:267-272.
8. Gordon LI, Molina A, Witzig TE, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103:4429-4431.
9. Gordon LI, Witzig TE, Molina A, et al. Yttrium-90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy produces high response rates and durable remissions in patients previously treated with B-cell lymphoma: updated results of a randomized controlled trial. Clin Lymphoma 2004; 5:98-101.
10. Schilder RJ, Molina A, Bartlett N, et al. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, folllicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2004; 19:478-481.
11. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3262-3269.
12. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3793-3803.
13. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-2463.
14. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336-4342.
15. Emmanouilides C, Witzig TE, Molina A, et al. Improved safety and efficacy of yttrium-90 ibritumomab tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade, follicular and transformed B-cell non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 2003; 22:595 (Abstract #2392).
16. Emmanouilides C, Murray J, Vo K, et al. Earlier treatment with yttrium 90 ibritumomab tiuxetan radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkin's lymphoma results with second-line therapy. Blood 2003; 102(suppl):306b (Abstract #4949).
17. Czuczman MS, Emmanouilides C, Witzig TE, et al. Multivariate analysis of prognostic factors correlated with response to 90Y ibritumomab tiuxetan radioimmunotherapy for non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 2002; 21:266a (Abstract #1062).
18. Emmanouilides C, Witzig TE, Gordon LI. Zevalin radioimmunotherapy (RIT) is safe and effective in geriatric patients with low grade, follicular or CD20+ transformed (LG/F/T) non-Hodgkin lymphoma (NHL). Proc Am Soc Clin Oncol 2001; 20:268a (Abstract #1143).
19. Witzig TE, Gordon LI, Gaston I, et al. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy of follicular NHL: results by follicular subtype. Proc Am Soc Clin Oncol 2002; 21:266b (Abstract #1063).
20. Younes A, Pro B, Delpassand E, et al. A phase II study of 90Yttrium-ibritumomab for the treatment of patients with relapsed and refractory mantle cell lymphoma Blood 2003; 102(suppl):406a (Abstract #1476).
21. Vose JM, Bierman P, Lynch JC, et al. Phase I clinical trial of Zevalin (90Y-ibritumomab) in patients with B-cell non-Hodgkin's lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ASCT). Blood 2003; 102(suppl):30a (Abstract #92).
22. Witzig TE, Molina A, Gordon LI, et al. Yttriurn 90 ibritumomab tiuxetan radioimmunotherapy induces durable remissions in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma: analysis of long-term responders. Blood 2003; 102(supppl):407a (Abstract #1480).
23. Ansell SM, Schilder RJ, Pieslor PC, et al. Anti-lymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan (Zevalin®) are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clin Lymphoma. In press.
24. Ansell SM, Ristow KM, Habermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3885-3890.
25. Witzig TE, Wiseman GA, Geyer S, et al. A phase I trial of two-sequential doses of Zevalin radioimmunotherapy for relapsed low-grade B-cell non-Hodgkin's lymphoma. Blood 2003; 102(suppl):406a (Abstract #1475).
26. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:1263-1270.
27. Czuczman M, Witzig TE, Gaston I, et al. Zevalin ™ radioimmunotherapy is not associated with an increased incidence of secondary myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). Blood 2002; 100(suppl):357a (Abstract #1386).
28. Kantarjian HM, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 1987; 14:435-443.
29. Leone G, Mele L, Pulsoni A, et al. The incidence of secondary leukemias. Haematologica 1999; 84:937-945.